vericiguat
Trade name: Verquvo
Small moleculeapprovedFast Track FDA
Approved
Jan 19, 2021
Clinical trial activity
30 trials · 23 clinical orgs · 1 marketing orgs
Phase 1
7
Phase 2
13
Phase 3
4
Phase 4
7
Earliest trial started Nov 1, 2013 (NCT01951638)
Timeline
2010s
Indications
Approved for
Studied for
- Acute Coronary Syndrome · Phase 4
- Angina Pectoris · Phase 2
- Brain Diseases · Phase 4
- Breast Neoplasms · Phase 2
- Cardiovascular Diseases · Phase 2
- Child · Phase 1
- Cognitive Dysfunction · Phase 2
- Coronary Artery Disease · Phase 1
- Coronary Disease · Phase 2
- COVID-19 · Phase 2
- Endothelial Cells · Phase 4
- Energy Metabolism · Phase 2
- Heart Diseases · Phase 2
- Heart Failure · Phase 4
- Heart Failure, Systolic · Phase 4
- Hypertrophy, Left Ventricular · Phase 2/Phase 3
- Inflammation · Phase 4
- Insulin Resistance · Phase 2
- Kidney Diseases · Phase 4
- Metabolic Diseases · Phase 2
- Metabolic Syndrome · Phase 2
- Metabolism · Phase 2
- Myocardial Infarction · Phase 4
- Obesity · Phase 2
- Pharmacokinetics · Phase 1
- Pulmonary Arterial Hypertension · Phase 4
- Systole · Phase 3
- Vascular Diseases · Phase 4
Mechanism of action
- Soluble guanylate cyclaseACTIVATOR
Soluble guanylate cyclase activator
- Soluble guanylate cyclaseAGONIST
Soluble guanylate cyclase agonist
Approval history
- approvedPriority reviewFast trackJan 19, 2021
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)Nc1c(N)nc(-c2nn(Cc3ccccc3F)c3ncc(F)cc23)nc1N- Mol. weight
- 426.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Black box warningFirst in class
Sources
- ChEMBLCHEMBL4066936 ↗
Also known as
- bay 1021189
- vericiguat
- vericiguat
- vericiguat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07047547 | N/A | Jun 1, 2025 | Shantou University |
| NCT06320951 | Phase 2 | May 1, 2025 | University of Alabama, Birmingham |
| NCT06812546 | Phase 4 | Apr 1, 2025 | Chongqing Medical University |
| NCT06671990 | Phase 4 | Dec 1, 2024 | Aarhus University, University of Copenhagen |
| NCT06601465 | Phase 2 | Nov 30, 2024 | Heart and Stroke Foundation of Canada, University of Alberta, University of Ottawa |
| NCT06239974 | N/A | Aug 1, 2024 | The University of Hong Kong |
| NCT06428383 | Phase 3 | Jul 3, 2024 | Merck |
| NCT06415227 | Phase 2 | Jul 1, 2024 | Bayer, University of Amsterdam |
| NCT06195930 | Phase 2 | Apr 18, 2024 | Bayer, Merck |
| NCT05704478 | Phase 4 | Jan 1, 2024 | University of Colorado, Denver |
| NCT06321094 | Phase 4 | Oct 1, 2023 | Nanjing Medical University |
| NCT05806138 | Phase 2 | Jul 17, 2023 | Memorial Sloan-Kettering Cancer Center, Merck |
| NCT05711719 | Phase 2 | Jun 16, 2023 | Johns Hopkins University, Merck |
| NCT05714085 | Phase 2/Phase 3 (Phase 3) | May 31, 2023 | Merck |
| NCT05812755 | Phase 4 | May 19, 2023 | National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University |
| NCT05697640 | Phase 2 | Feb 28, 2023 | Bayer, Humboldt University |
| NCT05658458 | Phase 4 | Dec 19, 2022 | Bayer |
| NCT05420012 | Phase 4 | Dec 1, 2022 | Merck, University of Utah |
| NCT05093933 | Phase 3 | Nov 2, 2021 | Merck |
| NCT05086952 | Phase 1 | Oct 12, 2021 | Bayer, Merck |
Showing 20 of 30 trials
Page 1 / 2
Organizations
Research & Development (23)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 15 | 12 | 4 | 2013 |
| Merck | For profit | 15 | 4 | 4 | 2014 |
| Canadian VIGOUR Centre | Academic/Hospital | 2 | 0 | 2 | 2016 |
| Duke University | Academic/Hospital | 2 | 0 | 2 | 2016 |
| University of Alberta | Academic/Hospital | 2 | 1 | 2 | 2016 |
| Aarhus University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Chongqing Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Heart and Stroke Foundation of Canada | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Humboldt University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Inova Health System | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2023 |
| Shantou University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| The University of Hong Kong | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Amsterdam | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2024 |
23 organizations
Page 1 / 2